Ethyl-EPA Treatment of Prodromal Patients

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Treatments: Eicosapentaenoic acid ethyl ester

Criteria

Inclusion Criteria:

• meets criteria for schizophrenia prodrome

Exclusion Criteria:

• any lifetime antipsychotic treatment